Business Matters: Eclipsed by Catastrophe

G. Steven Burrill;

Publication

Article

November 15, 2001

BioPharm International

BioPharm International-11-01-2001

Volume14

Issue 11

Business Matters: Eclipsed by Catastrophe

Author(s):

G. Steven Burrill

by G. Steven Burrill at Burrill & Company Despite stimulating and positive news for biotech product approvals and high-value deals this quarter, market performance has been shaped by the terrorist attacks and their aftermath.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Business Matters: Eclipsed by Catastrophe

Systematic Troubleshooting for LC/MS/MS: Part 1, Sample Preparation and Chromatography

Designs for Bioassays with Plate Location Effects

Liposomes (a Review), Part One: Manufacturing Issues

Simplifying Pharmacologic Analysis with Programmable Scientific Software

Outsourcing Outlook: Truth in Outsourcing

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Business Matters: Eclipsed by Catastrophe

Newsletter